The recent political developments have had a significant impact on the biotech sector, particularly affecting major players like BioNTech, Moderna, and Pfizer.
This has raised concerns among investors. It has led to a drop in share prices for these companies. Despite the short-term volatility, analysts believe that the long-term prospects for these companies, especially in cancer research and innovative therapies, remain promising.
BioNTech's recent acquisition of the Chinese biotech firm Biotheus is seen as a strategic move that could enhance its portfolio.
Pfizer is focusing on gene therapy and oncology projects to offset the decline in COVID vaccine sales.
Investors are left with the question of whether to buy, sell, or hold their positions in these biotech stocks. BioNTech's share price is currently hovering just above EUR 90, with a potential recovery if it rises above EUR 100. Pfizer's stock is trading between 23 and 25 US dollars, with indications of a bottom forming. Both companies have ongoing research and development initiatives that could drive future growth. It is important for investors to stay informed and vigilant as the situation develops, as the interplay of political decisions and scientific advancements will continue to shape the trajectory of these companies.